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Abstract
Introduction: Stem cells from adult tissues were considered for a long time as promising tools for regenerative
therapy of neurological diseases, including spinal cord injuries (SCI). Indeed, mesenchymal (MSCs) and neural crest
stem cells (NCSCs) together constitute the bone marrow stromal stem cells (BMSCs) that were used as therapeutic
options in various models of experimental SCI. However, as clinical approaches remained disappointing, we
thought that reducing BMSC heterogeneity should be a potential way to improve treatment efficiency and
reproducibility.
Methods: We investigated the impact of pure populations of MSCs and NCSCs isolated from adult bone marrow in
a mouse model of spinal cord injury. We then analyzed the secretome of both MSCs and NCSCs, and its effect on
macrophage migration in vitro.
Results: We first observed that both cell types induced motor recovery in mice, and modified the inflammatory
reaction in the lesion site. We also demonstrated that NCSCs but especially MSCs were able to secrete chemokines
and attract macrophages in vitro. Finally, it appears that MSC injection in the spinal cord enhance early
inflammatory events in the blood and spinal cord of SCI mice.
Conclusions: Altogether, our results suggest that both cell types have beneficial effects in experimental SCI, and
that further investigation should be dedicated to the regulation of the inflammatory reaction following SCI, in the
context of stem cell-based therapy but also in the early-phase clinical management of SCI patients.
Introduction
Regenerative processes are relatively modest in the
mammalian central nervous system (CNS), and stem
cell-based therapy has raised important hopes for treating
neurological diseases for many years. Indeed, patients suf-
fering from degenerative or traumatic pathologies of the
nervous system have to deal with heavy clinical, social and
psychological impairments, while only compensatory
attempts could be considered to reduce symptoms. Stem
cells from adult bone marrow stroma have been proposed
as highly powerful candidates in such therapies and con-
sidered worldwide in a large panel of animal models for
various neurological conditions, such as Parkinson’s dis-
ease, Alzheimer’s disease, Huntington’s disease, multiple
sclerosis, amyotrophic lateral sclerosis, stroke, or trau-
matic spinal cord injuries (reviewed in [1]). Beyond their
debated ability to transdifferentiate into neural cells, bone
marrow stromal stem cells (BMSCs) effectively show in-
teresting features, such as immunomodulating [2], neuro-
trophic [3], or pro-angiogenic activities [4]. These stem
cells were shown to efficiently enhance functional recov-
ery in experimental models of spinal cord injuries (SCI) by
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modulating diverse physiopathological events, such as in-
flammatory reaction, oxidative stress, apoptosis, angiogen-
esis, axonal growth, or myelination (reviewed in [5]).
BMSCs have subsequently been considered in a clinical
context for treating SCI patients [6]. If only modest en-
hancement was observed, additional investigation is re-
quired to identify the cellular and molecular mechanisms
underlying BMSC activity in the injured spinal cord, in
order to further improve patient outcome. Noteworthy,
the lack of exact phenotypic characterization of BMSCs
(due to the absence of specific membrane markers and
non-standardized culture methods) prompts supplemental
difficulty [7, 8]. Furthermore, it has been demonstrated
that the classically defined mesenchymal stem cells
(MSCs) from adult bone marrow are actually arising from
different embryonic lineages. Indeed, although adult
BMSCs were commonly considered to be of mesodermal
origin [9], several studies have conclusively shown that a
subset of adult BMSCs derives from the neural crest [10,
11]. Our group previously reported a complete compari-
son of bone marrow MSCs and neural crest stem cells
(NCSCs), and showed that both cell types were able to
give rise to functional neurons in vitro [12]. Even if those
cells failed to differentiate into neurons in experimental
models for Parkinson’s disease [13–16] and other neuro-
logical conditions such as SCI [1, 17, 18], BMSCs are still
considered as powerful candidates for cell therapy proto-
cols. Indeed, the literature largely associates the positive
impact of BMSCs in neurological disorders to their secre-
tome, composed of all the molecules and vesicles secreted
by these cells. BMSC secretome is enriched in growth and
neurotrophic factors, cytokines/chemokines, angiogenic
factors, etc., and could be extremely interesting from a
therapeutic perspective. Many studies have identified
secretome-related effects of BMSCs in vitro, but also in
animal models for different CNS pathologies, including
SCI [19–22]. Among other properties, BMSCs are able to
sense and modulate inflammatory reaction [23, 24] and
are, for instance, already used to reduce immune rejection
in graft-versus-host disease [25].
The aim of this study was to compare adult bone mar-
row MSCs and NCSCs properties, both in vitro and in
vivo, in the context of SCI-related inflammation. Indeed,
traumatic SCI encompasses many physiopathological
events including an intense inflammatory reaction that
starts directly after the lesion and persists chronically for
weeks to months [26]. Consequently, for many years,
SCI patients received methylprednisolone in attempt to
limit lesion extent and swelling as early as possible [27].
However, it is now well accepted that beyond the clas-
sical view about detrimental post-traumatic neuroin-
flammation, the immune system displays multiple
neuroprotective functions and requires a subtle regulation
[28, 29]. Systemic immune cells, such as granulocytes [30]
or monocytes/macrophages [31], play important roles in
CNS tissue regeneration after trauma. Macrophages are
the most studied immune cells in the context of SCI and
have already been tested in SCI patients [32]. In addition,
experimental data recently demonstrated that different
categories of macrophages (with distinct phenotypes or
origins) have distinct roles in SCI recovery [33–35].
The main objective of this paper was, therefore, to study
the immunomodulatory properties of both MSCs and
NCSCs, and their respective secretomes. We aimed to high-
light how each cell type could manage functional recovery
after SCI, by modulating the recruitment of immune cells
from the systemic blood towards the injured spinal cord.
Methods
Animal handling
Eight- to ten-week-old Wnt1-Cre/R26R-LacZ double trans-
genic mice [36] (obtained by mating C57Bl/6 J Wnt1-Cre
mice [37] and C57BL ROSA26R-LacZ mice [38]) were used
to isolate NCSC and MSC clones from adult bone marrow
stromal cell cultures (BMSCs). Ten- to twelve-week-old
wild type C57BL/6 J female mice were used as recipient
mice for graft experiments after spinal cord injury, in order
to facilitate bladder emptying and avoid urinary tract infec-
tions. Menstrual cycle was controlled at the day of surgery.
Animals were bred at the University of Liège Central
Animal facility. This study was approved by the Ethics
Committee of the Medicine Faculty of the University of
Liège (ethical permit 1200), and experiments were per-
formed in accordance with the rules set by this committee
and the Swiss Academy of Medical Sciences.
Cell culture, clonal selection of MSCs and NCSCs, and
preparation of MSC- and NCSC-conditioned medium
Eight- to ten-week-old Wnt1-Cre/R26R-LacZ double
transgenic mice [36] were used to isolate NCSC and
MSC clones from adult bone marrow stromal cell cultures
(BMSCs), obtained from femoral and tibial aspirations
and resuspended in MesenCult Medium (MesenCult,
Stem Cells Technologies, Grenoble, France). After 24 h,
non-adherent cells were removed. After reaching conflu-
ence, BMSCs were dissociated with 0.05 % trypsin-EDTA
(Life Technologies, Carlsbad, CA, USA) and then sub-
cultured (750,000 cells/25 cm2) at 37 °C, in a 95 % O2/5 %
CO2 atmosphere. For clonal selection, passage 5-BMSCs
were seeded in a 96-well plate at a mean dilution of 0.7
cell/well, in MesenCult Medium. Based on β-galactosidase
expression, we selected five clonal populations of NCSCs
and five clonal populations of MSCs. At confluence, cells
were dissociated with 0.05 % trypsin-EDTA and sub-
cultured under the same conditions [12]. For conditioned
medium (CM) preparation, two cultures of 500,000 cells
were prepared, respectively containing five NCSC clones
(NCSCmix) and four MSC clones (MSCmix) in equal
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number. Cell mixes were placed overnight at a density of
2,000 cells/cm2 in 5 mL of MesenCult (alone or supple-
mented with 1 μg/mL of Escherichia coli lipopolysacchar-
ide (E. coli LPS 055:B5, L2880, Sigma-Aldrich, Saint-
Louis, MO, USA)). Cells were then rinsed three times with
5 mL PBS, and MesenCult medium was replaced by 5 mL
serum-free DMEM for 24 h. After centrifugation and 0.22
um filtration, MSC-CM, LPSMSC-CM, NCSC-CM and
LPSNCSC-CM were stored at -20 °C.
Cytokine array and ELISA experiments
For the qualitative and quantitative analysis of MSC-CM
and NCSC-CM, Mouse Cytokine Array (ARY006,
R&D Systems, Minneapolis, MN, USA) and Mouse
Quantikine –G-CSF, M-CSF, CXCL1, CXCL2, CXCL10,
CXCL12, IL-6, CCL2, CCL5, sICAM-1, and TIMP-1-
ELISA kits (R&D Systems, Minneapolis, MN, USA) were
respectively performed with conditioned medium samples.
Spinal cord and plasma samples were also processed using
these assays, according to the manufacturer’s suggested
procedure.
Chemotaxis and metabolic assays – migration of
RAW264.7 macrophages in response to MSC- or
NCSC-conditioned medium
RAW264.7 macrophage cell line was used to test for the
chemoattractant power of MSC-CM or NCSC-CM. The
RAW264.7 cells were cultured in DMEM containing 10 %
decomplemented fetal bovine serum. After being labeled
with Cell Tracker Green (CTG) (Life Technologies, Carls-
bad, CA, USA) in serum-free DMEM, 100,000 RAW264.7
cells were placed on 5.2 mm-diameter filters (each con-
taining 100,000 5 um-pores) (ChemoTx, NeuroProbe,
Gaithersburg, MD, USA), above a bottom chamber con-
taining 30 μL of MSC-CM, LPSMSC-CM, NCSC-CM and
LPSNCSC-CM. The plate was incubated at 37 °C for 20 h.
After incubation, non-migrating macrophages were re-
moved from the top of the filter, and we quantified the per-
centage of filter area occupied by macrophages that
migrated throughout the filter, in response to MSC-,
LPSMSC-, NCSC- or LPSNCSC-CM. Metabolic assay was
performed using tetrazolium compound-based CellTiter
96H AQueous One Solution Cell Proliferation (MTS)
assay (Promega, Madison, WI, USA). A total of 10,000
RAW264.7 cells were seeded into wells of a 96-well plate.
After 20 h of culture in serum-free DMEM or in the
presence of 1 μg/mL LPS, MSC-CM, and NCSC-CM
(with or without LPS pretreatment), a MTS assay was
performed according to the manufacturer’s instructions.
Basically, after conversion of MTS into colored formazan,
absorbance of each well was evaluated at 490 nm. Each
experiment was performed in triplicate and repeated three
times (n = 3).
Spinal cord injury and cell transplantation experiment
Wild type C57BL/6 J female mice (10- to 12-weeks old)
were used as recipient mice for graft experiments after
spinal cord injury. Just before the surgery, two cell sus-
pensions containing, respectively, five NCSC clones and
four MSC clones in equal numbers were prepared.
Whereas NCSCmix were already traceable thanks to their
β-galactosidase activity, we needed to label MSCmix with
CTG to allow their traceability in vivo. The spinal cord
injury procedure and cell graft were performed as previ-
ously described [39]. Briefly, mice were anesthetized with
ketamine/xylazine and kept on a warm pad to undergo
T12 laminectomy. After being subjected to a moderate
(50 kDyn) T11/T12 contusion, SCI (IH-0400 Impactor,
Precisions Systems and Instrumentation, Fairfax, VA,
USA), mice immediately received three intralesional injec-
tions of 1 × 104 cells, inside the contusion site, 1 mm
above, and 1 mm below, respectively. This early timing of
transplantation was purposely selected in order to allow
grafted cell-related early neuroprotective and immuno-
modulatory effects to occur. After the surgery, mice re-
ceived saline injections to compensate for blood loss and
were placed in temperature-controlled incubators until
their complete awakening. Bladders were manually emp-
tied two times daily until spontaneous voiding returned.
Harvesting of spinal cord tissue and blood
Fresh spinal cord extract and whole blood were obtained
24 h and 7 days post-injury (dpi). Animals were eutha-
nized with a lethal dose of pentobarbital. Blood samples
were obtained by cardiac puncture and plasma was col-
lected into EDTA tubes. Spinal cord segments were im-
mediately removed (0.5 cm centered on the lesion site)
and placed into ice-cold PBS, before protein extraction
and western blot analyses. For histological analyses of
spinal cords, mice were sacrificed at 28 dpi by intracar-
diac perfusion of ice-cold PBS, followed by paraformal-
dehyde (PFA) 4 % (in PBS 0.1 M). Spines were dissected
and cords were immediately removed, post-fixed for 2 h
at 4 °C in the same fixative then immersed overnight in
a solution of sucrose 20 % (in PBS 0.1 M). Longitudinal
20 μm-sections were cut and stored at −20 °C.
Cell and tissue staining
Immunostainings
Briefly, slices (or cells) were incubated for 1 h with 10 %
normal donkey serum in PBS 0.1 M (supplemented with
0.3 % Triton X-100 for intracellular antigens). For specific
immunofluorescent staining, anti-nestin (1:300, NB100-
1604, Novus Biologicals, Littleton, CO, USA), anti-Sox2
(1:250; sc-17320, Santa Cruz, Dallas, Texas, USA), anti
p75NTR (1:200, AB1554, Millipore, Darmstadt, Germany),
anti-Sca-1 (1:100, ab25195, Abcam, Cambridge, United
Kingdom), anti-arginase 1 (1:100, 610708 BD Biosciences,
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Franklin Lakes, NJ, USA), anti-Iba1 (1:800, 019-19741,
Wako Chemicals, Richmond, VA, USA), anti-GFAP
(1:1000, 20334, Dako, Glostrup, Denmark), anti-laminin
(1:200, L9393, Sigma-Aldrich, Saint-Louis, MO, USA)
were diluted in PBS 0.1 M overnight at 4 °C. After PBS
washes, brain sections were incubated at room
temperature with fluorescein and rhodamine red X-con-
jugated secondary antibodies (1:500; Jackson Immunore-
search Laboratories, Westgrove, PA, USA) or with
peroxidase-coupled secondary antibodies (1:500, Dako,
Glostrup, Denmark) and diaminobenzidine revelation.
Nuclei were counterstained with Hoescht for fluorescent
staining. Image acquisition and analysis were performed
using a Zeiss AxioImager Z1 epifluorescent micro-
scope coupled with FluoView (Olympus), and Olym-
pus AX-70 microscope coupled with AnalySIS
software (Olympus).
Luxol Fast Blue-Neutral Red
Spinal cord sections were incubated in 0.0125 % Luxol
Fast Blue, as previously described [40]. Lesion volume
was evaluated by collecting maps of 15 sections and
performing 3D reconstructions via Mercator/Map3D
software (ExploraNova).
X-gal/hematoxylin staining
Stainings were performed as we previously described [13].
Western-blot analysis
Proteins were extracted from spinal cord segments col-
lected at 24 h and 7 days post-injury, resolved in Novex
4-12 % BisTris gels (NuPage, Life Technologies, Carls-
bad, CA, USA), and transferred onto a PVDF membrane
(Roche, Basel, Switzerland) according to standard proto-
cols. Blots were then probed with primary antibodies
targeting Ly6G/Gr-1 (1/500, MCA2387, AbD Serotec,
Kidlington, United Kingdom) and CD11b (1/500,
ab75476, Abcam, Cambridge, United Kingdom) at 4 °C
overnight. Secondary antibodies coupled to HRP (1/
3000, ab97057, Abcam, Cambridge, United Kingdom)
were applied for 1 h, and blots were revealed with a
chemiluminescent substrate (ThermoScientific, Wal-
tham, MA, USA) and imaged with the ImageQuant 350
scanning system (cooled-CCD camera, GE Healthcare,
Little Chalfont, Buckinghamshire, United Kingdom). α-
tubulin detection (1/10.000, ab56676, Abcam, Cam-
bridge, United Kingdom) was used as internal standard.
Expression levels were quantified with ImageMaster 1D
Prime Software (GE Healthcare, Little Chalfont, Buck-
inghamshire, United Kingdom).
Statistical analysis
Data were analyzed statistically using the Statistica 10
program (StatSoft, Tulsa, OK, USA). Results are reported
as mean ± standard error of the mean, with the n described
as the number of mice in each group. Level of statistical
significance was set at p < 0.05.
Results
In vitro characterization of MSCs and NCSCs from
Wnt1-CRE/R26R-LacZ mice bone marrow
Bone marrow stromal cells (BMSCs) have already been
considered in a wide variety of animal models for neuro-
logical diseases including spinal cord injury (SCI). Bene-
ficial effects are globally reported, despite a well-known
experimental variability. One explanation concerning
this variability would be the heterogeneity of bone mar-
row cell populations. Indeed, BMSCs are composed of
multiple progenitors and stem cell types with different
embryonic origins. In order to address this variability
problem and to better define the specific role of bone
marrow mesenchymal stem cells (MSCs) and bone
marrow neural crest stem cells (NCSCs) in tissue re-
generation after SCI, we decided to investigate pure
populations of MSCs and NCSCs separately. As previ-
ously described, we isolated both cell types from bone
marrow stromal cells from adult Wnt1-CRE/R26R-LacZ
mice [36], which allowed us to specifically discriminate
neural crest cells (which express LacZ) among the whole
BMSC population.
Since no specific marker would allow us to perform a
purification protocol to isolate MSCs and NCSCs from
adult bone marrow, we used a clonal selection method.
In order to limit the risk of clonal effect and rather get a
global population effect, four MSCs and five NCSCs
clones were, therefore, cultivated separately and respect-
ively pooled together (in equal number) as MSCmix and
NCSCmix, before each experiment. We first confirmed
that NCSCs underwent CRE-lox recombination and
lost PGK-Neomycin cassette, and that MSCs con-
served it (Fig. 1a). Despite a similar morphology, NCSCs
and MSCs exhibit different phenotypes. NCSCmix (β-
galactosidase-positive, Fig. 1e) expressed high levels of
Nestin, Sox2 (Fig. 1f ) and P75NTR (Fig. 1g), whereas
MSCmix were β-galactosidase-negative (Fig. 1b) and
Sox2-negative (Fig. 1c), and only display low expres-
sion of Nestin (Fig. 1c), and P75NTR markers (Fig. 1d),
while expressing Sca-1/Ly6 membrane receptor (Fig. 1d).
MSCs and NCSCs accelerate locomotor recovery in mice
with moderate spinal cord contusion injury
Many experimental studies have so far documented the
high potential of BMSCs in the treatment of experimen-
tal SCI, but unsatisfactory clinical applications prompted
us to further investigate the different mechanisms in-
duced by those cells. After characterizing two different
subsets of stem cells among the heterogeneous BMSC
population, we wanted to define the role MSCs and
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NCSCs could specifically play in the treatment of SCI
and the management of SCI-induced inflammatory reac-
tion. We, therefore, decided to inject MSCmix or
NCSCmix in a mouse model for contusive SCI. MSCmix
or NCSCmix were intraspinally transplanted directly after
a thoracic contusion injury in C57BL/6 J adult mice, and
PBS was injected as vehicle. Under those conditions, we
observed that MSCmix- and NCSCmix-transplanted mice
significantly recovered hindlimb motility starting from
day 5 post-injury compared to control mice (Fig. 2a)
(n = 6 to 7, repeated measures ANOVA and HSD
post-test, *p < 0.05; **p < 0.01; ***p < 0.001), according
to the Basso Mouse Scale [41]. We observed that the
time to reach score 4 (corresponding to plantar stepping)
was reduced in MSCmix- (6.50 ± 0.80 days, **p < 0.01) and
NCSCmix-injected mice (6.28 ± 0.83 days, **p < 0.01) com-
pared to PBS-injected control mice (13.16 ± 1.10 days)
(Fig. 2b). Similarly, the time to reach score 6 (correspond-
ing to motor coordination) was significantly shortened in
MSCmix- (9.33 ± 1.47 days, **p < 0.01) and NCSCmix-
injected mice (8.71 ± 1.39 days, **p < 0.01) compared to
controls (20.83 ± 2.02 days) (Fig. 2c) (n = 6 to 7, one-way
ANOVA and HSD post-test). Finally, 28 days post-injury,
control mice reached a BMS score that came closer to the
score of the cell-injected groups. However, these results
highlight a significantly accelerated motor recovery of
Fig. 1 Characterization of MSCmix and NCSCmix isolated from the bone marrow of adult Wnt1-CRE/R26R-LacZ mice. After recombination, NCSCs
from Wnt1-CRE/R26R-LacZ mice express LacZ gene. MSCs did not undergo Cre/Lox recombination and conserved the PGK-Neo cassette (a).
MSCmix are adherent fibroblast-like cells, do not express β-galactosidase (b) or Sox2 c (red), slightly express Nestin (c) (green), p75NTR (d) (red),
and Sca-1 (d) (green). NCSCmix have a similar morphology, express β-galactosidase (e), Nestin (f) (green), Sox2 (f) (red) and p75NTR (g) red), but
not Sca-1(g) (green). Scale bar = 20 μm. MSC mesenchymal stem cell, NCSC neural crest stem cell
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mice that received MSCmix or NCSCmix transplantation,
which should be considered of significant interest from a
clinical point of view.
MSCs and NCSCs transplantation modify the lesion
environment 28 days post-SCI
Four weeks after the injury/transplantation procedure,
we were not able to retrieve any β-galactosidase-positive
NCSCs or CTG-labeled MSCs. Indeed, it is well known
that BMSC integration and survival into the host spinal
cord tissue of experimental rodent models are very low
[42]. Still, we evaluated the size of SCI lesions in order
to attest to a protective effect of MSC and NCSC trans-
plantation that could be associated with an improved
locomotor recovery. We stained 28-day longitudinal
spinal cord sections with Luxol Fast Blue/Neutral Red
[40] and selected the lesioned area (Fig. 3b). Sections
were then assembled to obtain a 3D volume of the lesion
(Fig. 3a), which was then normalized to the initial im-
pact displacement, provided by the impactor software.
We observed that the lesion size tend to decrease in
MSCmix- and NCSCmix-grafted mice (in accordance with
the ameliorated locomotion) (Fig. 3b). We applied the
same selection of lesioned area on the directly adjacent
sections, and noticed that the percentage of GFAP-
immunoreactive (ir) (astroglial scar) and laminin-ir
area (blood vessels) in the lesion zone was similar
between the three groups (Fig. 3c, e) (n = 6 to 7,
one-way ANOVA, p > 0.05). Conversely, the percentage
of Iba1-ir area (macrophages) tended to increase in
sections corresponding to MSCmix-grafted spinal
cords (Fig. 3d) (n = 6 to 7, one-way ANOVA and HSD
post-test, p = 0.1).
Based on these results, we analyzed the expression of
arginase-1 which characterizes the anti-inflammatory
phenotype of myeloid immune cells [43]. We also had to
take into consideration that arginase-1 was also
expressed by different cell types in the spinal cord, [44],
but fortunately, as observed in our control condition
(Fig. 3f ), the basal expression level of arginase-1 was
close to background. In this context, we detected
arginase-1-ir cells in the epicenter of spinal cord lesions
from MSCmix- (Fig. 3h) and NCSCmix-grafted mice
(Fig. 3g), in a significantly higher number compared to
control mice (Fig. 3i) (n = 6 to 7, one-way ANOVA and
HSD post-test, *p < 0.05; ***p < 0.01). We quantified little
Fig. 2 MSCmix and NCSCmix intraspinal cell graft accelerates motor recovery in mice with moderate SCI. MSC-grafted mice and NCSC-grafted mice
recovered hindlimb motility faster than PBS-injected mice, as reflected by the Basso Mouse Scale scoring (a) (n = 6 to 7, repeated measures
ANOVA and HSD post-test, *p < 0.05; **p < 0.01; ***p < 0.001). Indeed, it appears that MSC- and NCSC-grafted mice reach score 4 (plantar stepping,
b) and score 6 (coordination, c) in a significantly reduced time interval (n = 6 to 7, one-way ANOVA and HSD post-test, **p < 0.01). MSC
mesenchymal stem cell, NCSC neural crest stem cell, SCI spinal cord injury, PBS phosphate-buffered saline, ANOVA analysis of variance,
HSD honestly significant difference
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rounded cells that expressed a high level of arginase-1.
These rounded arginase-1-ir cells (Fig. 3h’) were also
found close to laminin-ir blood vessels (Fig. 3j, k).
At this point of the study, we observed that even if
grafted cells were not recovered in the spinal cord tissue,
they apparently worked on the inflammatory environment
Fig. 3 MSCmix and NCSCmix intraspinal cell graft influences lesion environment. After 3D reconstruction of spinal cord sections (a) stained with
Luxol Fast Blue-Neutral Red (b), we evaluated the lesion volume in each group, which tends to be reduced in NCSC- (black) and MSC-grafted
mice (dark grey) compared to controls (light grey) (b). We translated the evaluated lesion area on the next adjacent section to quantify the
expression of GFAP, Iba1 and laminin. The GFAP-immunoreactive (ir) (c) and laminin-ir area (e) did not differ between the three groups, but the
Iba1-ir area was a bit increased in MSC-grafted spinal cord sections (d). We also observed the presence of arginase 1-ir cells, not in control mice
(f) but only in NCSC- (g) and MSC-grafted mice (h). The little rounded cells (h’) were more abundant in MSC- than in NCSC-grafted mice (i), and
were recovered close to laminin-ir blood vessels (j), (k). (n = 6 to 7, one-way ANOVA and HSD post-test, *p < 0.05; ***p < 0.01). Scale bar = 500 μm
(a to e), 200 μm (f to h), 20 μm (double, h’, j, k). MSC mesenchymal stem cell, NCSC neural crest stem cell, GFAP glial fibrillary acidic protein, ANOVA
analysis of variance, HSD honestly significant difference
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of the lesion and promoted an accelerated motor recovery
of SCI mice.
Characterization of MSC- and NCSC-secreted chemokines
and cytokines under normal and inflammatory conditions
Taking into account that MSCs and NCSCs seem to act
quite early on their neighboring tissue and lead to an in-
creased motor recovery as early as five days post-injury
without integrating the host tissue, we hypothesized that
cells could exert secretome-related activities. As previ-
ously mentioned, BMSCs can exert tissue repair by
modulating diverse physiopathological events through
the secretion of a wide variety of molecules, including
cytokines and chemokines that are able to modulate im-
mune cell recruitment and activity. In order to analyze
the secretome of MSCmix and NCSCmix, we collected
serum-free culture medium (DMEM) in which equiva-
lent numbers of cells were incubated for 24 h [MSC-
and NCSC-conditioned media (CM)]. Two sets of condi-
tions were compared: 1) MSC- or NCSC-CM without
stimulation; and 2) LPSMSC- or LPSNCSC-CM from cells
that were prestimulated with 1 μg/mL of lipopolysac-
charide (LPS), for 24 h (Fig. 4a). Indeed, it is well known
that LPS is able to induce the release of chemoattractant
cytokines or chemokines from different cell types [45],
and it was therefore interesting to mimic an inflam-
matory stimulus and analyze its effect on MSC and
NCSC secretomes. Before testing LPS effects on MSCs
and NCSCs, we confirmed from a previous microarray
experiment that both cell types expressed genes coding
for TLR4, and other downstream effectors (GSE30419),
allowing these cells to properly respond to LPS stimula-
tion [12].
We used a Mouse Cytokine Array to detect the differ-
ent cytokines and chemokines secreted by MSCs and
NCSCs. This qualitative analysis allowed us to observe
that MSCs secreted a wide variety of cytokines such as
CXCL10, CXCL1, M-CSF, CCL2, CXCL2, CCL5,
CXCL12, and TIMP-1. LPS pre-stimulation boosted
the secretion of some of these proteins and induced
the secretion of CCL1 and IL-6 in LPSMSC-CM.
Conversely, we noticed that the secretome of
NCSCmix was not as enriched and that LPS stimula-
tion did not induce such high modifications; still ,we
observed the presence of CXCL10, CXCL1, M-CSF,
CCL2 and TIMP-1 in NCSC-CM, and LPSNCSC-CM
(Fig. 4b).
ELISA arrays were then performed to obtain quantita-
tive confirmation of those results (Fig. 2c-l). We observed
that when stimulated with LPS, MSCmix drastically in-
crease the secretion of G-CSF, CXCL1, CCL5, CCL2, and
IL-6. CXCL12 was exclusively secreted by MSCmix, but
was not modified by LPS pre-treatment. When stimulated
by LPS, both cell types secreted slight amounts of CXCL2.
NCSCmix secreted CCL2 (more than MSCmix in basal con-
ditions), which was further increased by LPS pre-
conditioning. TIMP-1 was detected in high concentra-
tions, both in MSC-CM and NCSC-CM, either with or
without LPS pre-stimulation. Finally, M-CSF and CXCL10
were also detected, but in variable amounts (n = 5 to 7,
one-way ANOVA and HSD post-test, *p < 0.05, **p < 0.01,
***p < 0.001). Values are presented in Additional file 1:
Table S1.
MSC and NCSC secretomes stimulate the metabolic
activity and migration of RAW264.7 macrophages in vitro
In order to determine if MSC- and NCSC-secreted che-
mokines could exert functional chemoattraction, we
tested the effect of MSC-CM, LPSMSC-CM, NCSC-CM
and LPSNCSC-CM on the migration of RAW264.7 mac-
rophages. These cells were subjected to chemotaxis
through 5 μm-pores (Fig. 5a), and we calculated the per-
centage of filter area that was occupied by migrated
cells. After 20 h, we observed that few macrophages pas-
sively migrated across the filter in the presence of
DMEM (8.12 ± 1.06 %, Fig. 5b, h). LPS (1 μg/mL) was
used as a positive control and considerably increased the
migration of macrophages (50.42 ± 6.37 %, Fig. 5c, h). In
the presence of MSC-CM, the number of macrophages
recovered on the bottom side of the filter was slightly in-
creased compared with DMEM (19.44 ± 0.31 %, p = 0.1)
(Fig. 5d, h), but massively enhanced in the presence of
LPSMSC-CM (38.93 ± 3.66 %, ***p < 0.001) (Fig. 3e, h).
No significant chemoattractant effect was observed for
NCSC-CM compared to the control condition (10.83 ±
0.47 %, p > 0.5) (Fig. 5f, h); however, a significant in-
crease in macrophage migration was observed in the
presence of LPSNCSC-CM (30.98 ± 0.47 %, **p < 0.01)
(Fig. 5g, h) (n = 3, one-way ANOVA and HSD post-test,
**p < 0.01, ***p < 0.001). Interestingly, these observations
matched our previous results, showing that NCSCmix,
but especially MSCmix secreted massive concentrations
of chemokines when prestimulated with LPS. We also
confirmed that LPSMSC-CM and LPSNCSC-CM in-
creased the metabolic activity of RAW264.7 macro-
phages after 20 h, as attested by MTS enzymatic
assay (Fig. 5i) (n = 3, one-way ANOVA and HSD
post-test, **p < 0.01, ***p < 0.001). Note that
RAW264.7 macrophages do not exhibit any modifica-
tion in membrane marker expression or secretion in
response to MSC-CM or NCSC-CM (Additional file 3:
Figure S2).
Additionally, we observed that incubation with MSC-
CM or NCSC-CM did not modify the phenotype of
RAW264.7 macrophages, which all express CD68,
CD206, arginase-1, Iba1, CX3CR1, and CD11b in basal
conditions and in the presence of CMs. Likewise,
MSC-CM and NCSC-CM did not change the secretion
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Fig. 4 Qualitative and quantitative analysis of MSCmix- and NCSCmix-secretome. NCSCmix- and MSCmix-conditioned media (CM) are prepared by
culturing MSCmix and NCSCmix in serum-free DMEM for 24 h (with or without stimulation by 1 μg/mL LPS: LPSMSC-CM and LPSNCSC-CM) and analyzed
by Mouse Cytokine Array (a). Qualitative analysis of arrays revealed the presence of different chemokines and cytokines, especially present
in MSC-secretome (b), and their concentration in each CM sample was assessed by ELISA assays. We observed an increased concentration of G-CSF (c),
CXCL1 (d), CCL5 (e), IL-6 (f) in LPSMSC-CM, whereas CXCL12 was present in both MSC-CM and LPSMSC-CM (g). CXCL2 was present in very
low concentrations in LPSMSC-CM and LPSNCSC-CM (h). CCL2 was more concentrated in NCSC-CM than in MSC-CM, but increased in both
groups when prestimulated with LPS (i). TIMP-1 was equally secreted in all conditions (j), while M-CSF (k) and CXCL10 (l) were present in
variable concentrations. (n = 5 to 7, one-way ANOVA and HSD post-test, *p < 0.05, **p < 0.01, ***p < 0.001). For values, see Additional file 1:
Table S1. MSC mesenchymal stem cell, NCSC neural crest stem cell, DMEM Dulbecco’s modified Eagle’s medium, LPS lipopolysaccharide,
ELISA enzyme-linked immunosorbent assay, G-CSF granulocyte colony-stimulating factor, CXCL C-X-C motif ligand, CCL C-C motif ligand,
IL-6 interleukin-6, TIMP1, tissue inhibitor of metalloproteinases 1, ANOVA analysis of variance, HSD honestly significant difference
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profile of RAW264.7 macrophages (Additional file 2:
Figure S1).
With the help of this in vitro migration assay, we ob-
served that LPS-stimulated MSC- and NCSC-secreted
chemokines efficiently stimulate the metabolic activity
and the migration of macrophages. These results in-
duced us to hypothesize that once inside a lesioned
spinal cord, MSCs and NCSCs would be able to sense
inflammatory stimuli and secrete chemokines that re-
cruit immune cells towards the injury site.
MSCs seem to recruit immune cells in blood and spinal
cord of mice 24 h to seven days after spinal cord injury
In order to determine the inflammatory events occur-
ring acutely after the contusion that might explain
our observations at 28 days post-injury, we collected
the contused spinal cord tissue as well as the systemic
blood of mice, 24 h and seven days following the
intraspinal transplantation of MSCmix and NCSCmix
(Fig. 6a). In order to investigate the molecular events
that could reflect inflammatory reaction, we compared
MSCmix- and NCSCmix-grafted SCI mice with PBS-injected
SCI mice and uninjured (UI) mice (only subjected to
laminectomy). The complexity of both blood and
spinal cord extracts may explain the disparities that
we observed between the different mice of each single
group, giving rise to an unexpectedly high variability
(n = 6 to 7, one-way ANOVA and HSD post-test, p > 0.05).
Nevertheless, cytokine arrays (data not shown) and
ELISA confirmations highlighted an increased plasmatic
Fig. 5 Effects of MSC- and NCSC-secretome on RAW264.7 macrophages migration and metabolic activity in vitro. We evaluated the chemoattractive
properties of MSC and NCSC secretome by placing RAW264.7 macrophages on the top of a 5 μm-filter, with MSC-CM, LPSMSC-CM, NCSC-CM or
LPSNCSC-CM in the bottom chamber (a). After 20 h, migration rate was assessed by the evaluation of the filter area occupied by macrophages.
Passive migration was observed in response to serum-free DMEM (b, h), but drastically increased in response to LPS (c, h). MSC-CM slightly
increased macrophage migration (d, h), but LPSMSC-CM was more efficient (e, h). NCSC-CM did not significantly induce macrophage migration
(f, h), while LPSNCSC-CM also increased it (g, h). MTS metabolic assay also showed that LPSMSC-CM and LPSNCSC-CM increased the metabolic
activity of RAW264.7 cells i (n = 3, one-way ANOVA and HSD post-test, **p < 0.01, ***p < 0.001). Scale bar = 50 μm. MSC mesenchymal stem cell,
NCSC neural crest stem cell, CM conditioned medium, LPS lipopolysaccharide, DMEM Dulbecco’s modified Eagle’s medium, ANOVA analysis of
variance, HSD honestly significant difference
Neirinckx et al. Stem Cell Research & Therapy  (2015) 6:211 Page 10 of 15
Fig. 6 Early immune cell recruitment is slightly increased in the blood and spinal cord of MSC-grafted mice. We collected spinal cords and plasma
of mice, 24 h (white bars) and seven days (dark bars) post-injury (a). We observed that the concentration of G-CSF in the plasma of MSC-grafted
mice was slightly increased after 4 h compared to other groups (b), and the concentration of sICAM-1 as well (c), while both markers returned to
low levels after seven days. Additionally, the expression of Gr-1 (reflecting the presence of granulocytes) was slightly increased in MSC-grafted
spinal cords at 24 h, and returned to low levels after seven days (d) while the expression of CD11b increased at this delay (e). Interestingly, the
concentrations of CCL5 and CXCL1 were also slightly boosted after 24 h in MSC-grafted spinal cords (f, h), while CCL2 tended to increase in both
MSC- and NCSC-grafted groups (g). MSC mesenchymal stem cell, G-CSF granulocyte colony-stimulating factor, sICAM1 soluble intercellular
adhesion molecule, CCL C-C motif ligand, CXCL C-X-C motif ligand, NCSC neural crest stem cell
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concentration of G-CSF (Fig. 6b) and sICAM-1 (Fig. 6c),
24 h post-injury, in mice receiving MSCmix. The same
profile of data distribution was noticed after 24 h when
looking at the level of Gr-1/Ly6G expression (mostly
reflecting the presence of granulocytes) (Fig. 6d) as well as
the concentration of CCL5 (Fig. 6f) and CXCL1 (Fig. 6h)
in the spinal cord of MSCmix-grafted mice (n = 7,
Spearman correlation test, *p < 0.05). Conversely, the
concentration of CCL2 was slightly increased in both
MSCmix- and NCSCmix-grafted mice (in accordance
with the secretion of CCL2 by both cell types)
(Fig. 6g). After seven days, the level of CD11b expression
(mostly reflecting the presence of monocytes/macrophages)
was also slightly higher in the MSCmix-injected group
(Fig. 6e), whereas most of other parameters returned
to initial levels.
Discussion
For many years, bone marrow stromal stem cells
(BMSCs) have been considered as useful tools for treat-
ing nervous system diseases in experimental research.
Despite the demonstration of important benefits, crit-
ical information about the specific action of these
cells in neurological lesions and repair is further re-
quired. As strongly suggested by the literature in the
field, BMSCs act through paracrine secretion of
growth factors, cytokines, chemokines, and other sig-
naling molecules. This is of particular significance re-
garding physiopathological events that occur after a
traumatic spinal cord injury (SCI), which encompass
an intense inflammatory reaction that needs to be
finely regulated.
In our study, we isolated two BMSC subpopulations,
namely mesenchymal- (MSCs) and neural crest-derived
stem cells (NCSCs), which we previously characterized
in [12], and we observed that both MSCs and NCSCs
significantly accelerate motor recovery when grafted
intraspinally in mice with moderate SCI. This observa-
tion disproved our first hypothesis, namely that the vari-
ability of BMSC-based cell therapy results was due to
the gathering of populations with diverse embryonic ori-
gins. We also observed that both MSC and NCSC graft
induced a slight tissue sparing. Nevertheless, a precise
identification and quantification of the axonal fibers that
remain after lesion and/or are protected by grafted MSC
and NCSC would more reliably correlate with improved
motor recovery [46]. Furthermore, MSC and NCSC graft
modified the lesion environment, as mainly depicted by
the presence of arginase 1-expressing cells. Indeed,
arginase-1 is commonly associated with an anti-
inflammatory phenotype and metabolism [43] in im-
mune cells, such as macrophages [47] or granulocytes
[48]. We then formulated the hypothesis that MSC- and
NCSC-induced motor recovery could be associated with a
beneficial modulation of the inflammatory reaction. As we
previously mentioned, peripheral blood monocytes are
required for tissue repair after SCI [33], likely after being
primed into an anti-inflammatory phenotype in the
choroid plexus [34]. This hypothesis would then confirm
recent data showing that BMSCs have beneficial effects in
SCI mice by modulating the recruitment or the activity
of alternatively activated macrophages [49, 50] and,
therefore, enhancing tissue repair and motor behavior.
To support such a hypothesis, we showed that MSCs
and NCSCs secrete various chemokines and cytokines,
particularly when stimulated by E. coli lipopolysacchar-
ide (LPS). We observed that after LPS stimulation, MSCs
specifically secrete G-CSF, CXCL1, IL-6, CCL5, and
CXCL12, which are almost absent in the NCSC secre-
tome. These observations are in agreement with the high
chemoattractant power of MSC secretome on RAW264.7
macrophages in vitro, since the role of these chemokines
on immune cell recruitment is well described. Indeed,
CXCL1, CXCL2, CCL5, and G-CSF are involved in the
mobilization of neutrophils or monocytes in inflammatory
conditions [51], including in brain tissue inflammation
[52, 53], while CXCL12 enhances migration of diverse cell
types in the organism [54]. IL-6 is a multifunctional neu-
rotrophin and cytokine involved in neuronal survival,
hematopoiesis, immune response, and systemic reaction
to trauma [55]. Finally, CCL2 (also called monocyte
chemoattractant protein 1 or MCP-1) is well known to
stimulate macrophage migration under a wide variety of
physiological or pathological conditions in vitro [56, 57]
and in vivo [58, 59]. According to these data, we can infer
that CXCL1, IL-6, G-CSF CXCL2, CXCL12, and CCL2
are together responsible for the chemoattractant action of
MSCmix, which is further amplified when cells are presti-
mulated with LPS (correlated with increased concentra-
tions of chemokines). On the other hand, in vitro assays
have shown that only 10 ng/mL of CXCL1 is required to
enhance migration of neutrophils [60], and we could as-
sume that CXCL1 presence in LPSMSC-CM could trigger
chemotaxis by itself. Conversely, the NCSC secretome is
less enriched, and the presence of CCL2 only may not be
sufficient to induce chemoattraction at a similar level.
Indeed, when used for macrophage migration assays,
CCL2 is at least concentrated at 100 ng/mL [56, 57], and
its concentration in NCSC-CM or LPSNCSC-CM does not
reach this threshold. Nevertheless, we obviously consider
the possibility that the combination of CCL2 with low
levels of CXCL1, CXCL2, and IL-6 would be able to in-
duce migration of RAW264.7 cells.
Finally, we observed that stem cell transplantation
(and more especially MSCs) seemed to enhance early in-
flammatory events in blood and spinal cord tissue, as
reflected by high concentration of plasmatic G-CSF and
sICAM-1 and the presence of CXCL1, CCL2, CCL5, and
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Gr-1-expressing granulocytes in the spinal cord 24 h
post-SCI. Immune cell infiltration theoretically occurs in
the first week following SCI [26, 61]; the signs of early
amplified immune cell recruitment that we observed
here were correlated with the early acceleration of motor
recovery in MSC- and NCSC-grafted mice, which started
around five days post-injury. It has been recently shown
that neutrophil recruitment is mandatory in SCI repair
[30, 62], so we could imagine that neutrophils could
themselves have a specific activity in the lesioned spinal
cord. Nonetheless, we also observed a slight increase in
the number of macrophages in the lesion at 7 and
28 days post-injury, which could reflect macrophage re-
cruitment that would be subsequent to neutrophil
mobilization. Moreover, the presence of arginase-1-
expressing cells, 28 days post-injury in the spinal cord
and the slight tissue sparing seem to be remaining signs
of a beneficial increased inflammatory reaction in the le-
sion area. It is now of huge importance to define the
precise inflammatory sequence that is required for a
suitable repair of the spinal cord tissue.
Conclusion
In conclusion, our data suggest that pure populations of
MSCs and NCSCs isolated from the adult bone marrow
both have beneficial effects in SCI mice and the purifica-
tion of these different subsets does not overtake the ef-
fects which are described with the whole BMSC
population [5]. Altogether, this study confirms that great
interest should be dedicated to the regulation of inflamma-
tory reactions by exploring the pathways of chemokine-
associated immune cell recruitment and activity [28] trig-
gered by SCI and stem cell therapy. Despite the fact that
the use of experimental models for SCI requires care-
ful interpretation, new insights in the modulation of
SCI-associated inflammation will further provide new
tools and new therapeutic approaches that will finally
improve recovery of SCI patients.
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observed that when placed in serum-free DMEM, or in MSC- or NCSC-CM,
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